Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy York

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Data Science Journal|April 10, 2019
What Do We Know About the Stewardship GapJeremy York, Myron Gutmann, Francine Berman
Bioorganic & Medicinal Chemistry Letters|November 30, 2006
Design and synthesis of a novel class of dual PPARgamma/delta agonistsIsabel C Gonzalez, Jason Lamar, Fatima Iradier, et al.
Journal of Medicinal Chemistry|September 15, 2006
Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profileYanping Xu, Garret J Etgen, Carol L Broderick, et al.
Journal of Medicinal Chemistry|April 2, 2005
Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacyAlfonso de Dios, Chuan Shih, Beatriz López de Uralde, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Data Science Journal|April 10, 2019
What Do We Know About the Stewardship GapJeremy York, Myron Gutmann, Francine Berman
Bioorganic & Medicinal Chemistry Letters|November 30, 2006
Design and synthesis of a novel class of dual PPARgamma/delta agonistsIsabel C Gonzalez, Jason Lamar, Fatima Iradier, et al.
Journal of Medicinal Chemistry|September 15, 2006
Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profileYanping Xu, Garret J Etgen, Carol L Broderick, et al.
Journal of Medicinal Chemistry|April 2, 2005
Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacyAlfonso de Dios, Chuan Shih, Beatriz López de Uralde, et al.
Pageof 1